Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Raddnaron Jul 19, 2020 11:23pm
122 Views
Post# 31288973

RE:covid stock

RE:covid stock If you can work, work and save. Let your share count do its work. In regards to the other covid stocks, only two have received “better news” due US funding and joining Operations Warp Speed. Both of them are above the $80 USD mark and in terms of testing are behind ifenprodil by a complete stage. Obviously we’re comparing a vaccine stock to a treatment, but in terms of news and progress, AGNPF is only so cheap right now because their PR isn’t labeled for US release. It can’t run in the US, so must of the trading platforms can’t touch their PR. They can report on the gains, and until Thursday/Friday there wasn’t anything to write about. Now there is.

I know a lot of people like to talk about $1-$4 mark on AGNPF, but if you’ve followed the other covid stocks, their weekly gains of 1000% based off less news (much less) than what AGNPF has already accomplished, it’s easy to believe this stock pushing $10-$20 with positive testing results IN a US press release.
<< Previous
Bullboard Posts
Next >>